Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!

被引：0
|
作者：
Koufakis, Theocharis [1 ]
Popovic, Djordje S. [2 ,3 ]
Papadopoulos, Christodoulos [4 ]
Giouleme, Olga [5 ]
Doumas, Michael [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Propedeut Dept Internal Med 2, Thessaloniki 54642, Greece
[2] Univ Novi Sad, Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Disorders, Novi Sad, Serbia
[3] Univ Novi Sad, Med Fac, Novi Sad, Serbia
[4] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Dept Cardiol 3, Thessaloniki, Greece
[5] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Propedeut Dept Internal Med 2, Gastroenterol & Hepatol Div,Med Sch, Thessaloniki, Greece
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 02期
关键词：
MAFLD; cardiovascular risk; MACE; pharmacotherapy; NONALCOHOLIC STEATOHEPATITIS;
D O I：
10.1080/14656566.2024.2312239
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：123 / 126
页数：4
相关论文
共 50 条
  • [41] Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease Reply
    Yeoh, Aaron
    Cheung, Ramsey
    Ahmed, Aijaz
    Chitnis, Amit S.
    Do, Albert
    Wong, Robert J.
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (01): : E15 - E15
  • [42] Impact of sexual dimorphism on liver damage in patients with metabolic-dysfunction associated steatotic liver disease
    Dileo, E.
    Rosso, C.
    Parasiliti-Caprino, M.
    Caviglia, G. P.
    Ponzetto, F.
    Leoni, L.
    Pennisi, G.
    Armandi, A.
    Guariglia, M.
    Saba, F.
    Maccario, M.
    Petta, S.
    Mengozzi, G.
    Bugianesi, E.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
  • [43] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IS A SEXUAL DIMORPHIC DISEASE IN PEOPLE WITH HIV
    Kablawi, Dana
    Tadjo, Thierry Fotsing
    Milic, Jovana
    Elgretli, Wesal
    Gioe, Claudia
    Lebouche, Bertrand
    Cinque, Felice
    Ballesteros, Luz Ramos
    Cascio, Antonio
    Guaraldi, Giovanni
    Mazzola, Giovanni
    Sebastiani, Giada
    HEPATOLOGY, 2023, 78 : S1011 - S1012
  • [44] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    JHEP REPORTS, 2023, 5 (09)
  • [45] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [46] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [47] Prevalence of metabolic dysfunction associated fatty liver disease in people with type 1 diabetes
    Bellido, V.
    Amuedo, S.
    Remon-Ruiz, P.
    Roque-Cuellar, C.
    Jimenez-Sanchez, A.
    Gros-Herguido, N.
    Lopez-Gallardo, G.
    Pinar-Gutierrez, A.
    Soto-Moreno, A.
    DIABETOLOGIA, 2024, 67 : S498 - S499
  • [48] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE AND RISK OF CARDIOVASCULAR DISEASE MORTALITY AMONG NON-HISPANIC BLACKS
    Dai, Wei
    Foster, Kristoff
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 708 - 708
  • [49] Cardiovascular disease in metabolic-associated fatty liver disease
    Adams, Leon A.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (02) : 81 - 86
  • [50] The importance of age for liver-related mortality in patients with metabolic-dysfunction associated steatotic liver disease
    Bjornsson, Einar S.
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (01) : 124 - 127
12345